NCT06843304 The Intelligent Prevention And Control System And Strategy For The Whole Disease Cycle Of Diabetic Nephropathy
| NCT ID | NCT06843304 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese PLA General Hospital |
| Condition | Diabetic Nephropathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2024-01-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Diabetic nephropathy is one of the most severe microvascular complications of diabetes and a major cause of premature death and disability. It has become a leading cause of end-stage renal failure both in China and worldwide, consuming substantial medical resources. The establishment of a comprehensive regulatory system for the development and progression of diabetic nephropathy is a critical need for effective prevention and control. However, there is a lack of representative cohorts covering the entire disease cycle of diabetic nephropathy both domestically and internationally, creating technical bottlenecks in comprehensively describing its developmental patterns. This project aims to expand and integrate existing large-sample natural population cohorts and prospective follow-up cohorts covering the entire disease cycle of diabetes and diabetic nephropathy. It will construct a panoramic life database to identify risk factors, clinical phenotypes, and multimodal biomarkers at different disease stages. By integrating multi-organ interactions (e.g., kidney, eye), the project will establish novel imaging and functional assessment technologies for microvascular complications. Utilizing artificial intelligence to process multimodal medical data, it will build and validate risk prediction models and evaluation systems for the entire disease cycle of diabetic nephropathy. The project will develop effective intelligent prevention and treatment strategies for diabetic nephropathy, promote the adoption of new technologies, and establish a medical quality control system to provide services for medical institutions. Ultimately, it aims to improve and sustain medical quality, reducing the incidence of end-stage renal disease.
Eligibility Criteria
T2DM Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * A history of type 2 diabetes for more than 5 years * Negative proteinuria * Creatinine is normal * Good compliance, voluntarily sign informed consent Exclusion Criteria: * Incomplete medical records * Lack of fundus microvascular examination or new imaging technology examination results data * Combined with autoimmune diseases and tumors Type 2 diabetes patients undergoing renal biopsy Inclusion Criteria: * Age ≥18 years old, gender is not limited * Diagnosed with type 2 diabetes * Kidney damage (microalbuminuria or dominant albuminuria or renal insufficiency) * Have undergone renal puncture biopsy and have complete renal pathological diagnosis data * Sign informed consent voluntarily Exclusion Criteria: * Gestational diabetes mellitus, special type diabetes mellitus * Patients with hereditary kidney disease * Combined with autoimmune diseases * Diabetic nephropathy The indicators in the comprehensive assessment model of the risk of renal progression could not be obtained * There were pregnancy plans in the study period
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06843304 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetic Nephropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06843304 currently recruiting?
Yes, NCT06843304 is actively recruiting participants. Contact the research team at shengdai26@163.com for enrollment information.
Where is the NCT06843304 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06843304 clinical trial?
NCT06843304 is sponsored by Chinese PLA General Hospital. The trial plans to enroll 2,000 participants.